Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC), Pacira Pharmaceuticals (NASDAQ: PCRX) and Theravance Biopharma (NASDAQ: TBPH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alphatec Holdings (ATECResearch Report), Pacira Pharmaceuticals (PCRXResearch Report) and Theravance Biopharma (TBPHResearch Report) with bullish sentiments.

Alphatec Holdings (ATEC)

In a report released today, Sean Lee CFA from H.C. Wainwright reiterated a Buy rating on Alphatec Holdings, with a price target of $19.00. The company’s shares closed last Tuesday at $14.27.

According to TipRanks.com, CFA is a 3-star analyst with an average return of 13.5% and a 39.6% success rate. CFA covers the Healthcare sector, focusing on stocks such as ThermoGenesis Holdings, CASI Pharmaceuticals, and Gritstone Oncology.

Alphatec Holdings has an analyst consensus of Strong Buy, with a price target consensus of $22.00, representing a 48.2% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $22.00 price target.

See today’s analyst top recommended stocks >>

Pacira Pharmaceuticals (PCRX)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals, with a price target of $84.00. The company’s shares closed last Tuesday at $60.79.

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 5.5% and a 47.1% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Satsuma Pharmaceuticals.

Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $80.13, representing a 28.0% upside. In a report issued on July 26, J.P. Morgan also upgraded the stock to Buy with a $75.00 price target.

Theravance Biopharma (TBPH)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Theravance Biopharma today and set a price target of $32.00. The company’s shares closed last Tuesday at $13.63, close to its 52-week low of $12.72.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 15.3% and a 51.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Theravance Biopharma with a $29.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.